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acceptable incidence of side effects was recorded. 
Furthermore, it was possible to avoid colostomy in a 
significant proportion of patients. 
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Purpose or Objective: To define the Maximum Tolerated 
Dose (MTD) of Middle Half Body (MHB) Radiotherapy (RT) 
delivered with a conformal 3D technique and twice daily 
fractionation in prostate cancer (PC) multiple bone 
metastases. 
 
Material and Methods: A phase I trial was designed with two 
level of dose: 13 Gy (3.25Gy per fraction) and 15 Gy (3.75 Gy 
per fraction). Eligibility criteria were: histological confirmed 
PC, symptomatic and or impending for fracture multiple bone 
metastases, ECOG performance status 0-4, expected survival 
>3 months, and adequate bone marrow function. 
Radiotherapy was delivered using a 3D conformal technique 
twice daily in 2 sequential days, with at least 8 hours interval 
between fractions. Cohort of 6-12 patients were recruited in 
order to define the MTD (any acute toxicity > grade 3 of 
RTOG scale). Pain and quality of life were recorded using 
analogue-visual scales (VAS and CLAS). Clinical target volume 
was defined as pelvic bones, involved femurs + lumbar spine. 
Planning target volume was defined as the CTV + 1 cm. 
 
Results: From June 2010 to November 2014, 22 patients 
(median age 73 years; range 58-86) were enrolled. In Figure 1 
treatment volumes are described. 
 
 
 
At diagnosis, all patients (100%) reported pain. Clinical pain 
remission (complete or partial) was observed in 95% of 
patients. Six patients (27.3%) had a complete symptoms 
resolution and 15 (68.2%) had a partial symptom control. Pain 
worsening after radiation treatment was recorded only in 1 
patient. On the basis of analogue-visual scales a significant 
decrease of pain was recorded (mean VAS pre RT versus post 
RT: 4.6 versus 3,0; p=0.034; mean pain score pre RT versus 
post RT: 3.1 versus 1,9; p=0.069; mean drug score pre RT 
versus post RT: 3.9 versus 2,5; p=0.088). Skin and 
gastrointestinal acute toxicities were only grade 1-2. With a 
median follow up of 6 months (range 1-26) no late toxicity 
was recorded. 
 
Conclusion: An accelerated MHB RT treatment with twice 
daily fraction on bone metastases from PC was well tolerated 
up to 15 Gy. A phase II study is ongoing to confirm efficacy on 
pain control and quality of life. 
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Purpose or Objective: To evaluate the factors associated 
with treatment response (relieve of SVCS) and overall 
survival. 
 
Material and Methods: Thirty one patients with SVCS 
between 2012-2015 were analyzed. The end points were: 
overall survival and SVCS resolution. SVCS resolution was 
determined as the absence of symptoms related to the 
compression of superior vena cava. The variables tested 
were: sex (male vs female), age (<50 years vs > 50 years), 
primary site (lung vs others), KPS (<70 vs >/= 70), previous 
palliative RT (no vs yes), BED Gy10 dose (<25 vs > 25), more 
than 1 year of the initial diagnosis (no vs yes), tumor size 
(<10 cm vs >/= 10 cm), and number of previous 
chemotherapy (CT) lines (0 or 1 vs 2 or more), presence of: 
bone mets (no vs yes), central nervous system (SNC) mets (no 
vs yes), lung mets (no vs yes), liver mets (no vs yes), lymph 
node mets (no vs yes) and SVCS resolution (no vs yes). 
 
Results: The mean follow-up time of the patients alive was 
376 days (median 241 days). The 6-months and 1-year OS 
survival were 31.5 % and 18 %, respectively. Factors 
influencing positively the survival in univariate analysis were: 
KPS >/= 70 (p=0.001), 0 or 1 previous CT lines (p=0.012), 
diagnosis <1y (p=0.007), no bone mets (p=0.010), no lung 
mets (p=0.011), no liver mets (p=0.031) and SVCS resolution 
(p<0.001). In multivariate analysis only SVCS resolution 
(p=0.005) remained significant and no lung metastasis was 
marginally related (p=0.060). The overall SVCS resolution 
rate was 84% (12/25 cases). Nineteen patient were treated 
with radiotherapy (RT), four patient with chemotherapy and 
2 patients with RT + CT. Six cases receive no treatment (3 
because of extremely low KPS and 3 because of the risks of 
re-irradiation) and were excluded from the efficacy and 
multifactorial analysis. None of the variables tested 
influenced the treatment response rate. 
 
Conclusion: Treatment response rate was more than 80 % 
and it was the strongest factor associated with overall 
survival. This fact encourages the indication of treatment 
even in patients with low performance status or previous 
cervico-thoracic radiotherapy, after a risk-benefit analysis. 
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Purpose or Objective: The aim of this analysis was to 
determine the risk of vertebral compression fracture (VCF) 
following spine radiotherapy (RT) specific to colorectal 
cancer (CRC) spinal metastases, and to determine clinical 
predictors 
 
Material and Methods: We retrospectively reviewed 267 
spinal segments (176 metastatic and 91 non-metastatic 
vertebras) in 66 patients, which were irradiated for pain 
palliation between 2007 and 2014. The primary endpoint was 
development of a VCF following RT, either a de novo VCF or 
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progression of a baseline VCF. Each metastatic spinal 
segment was also evaluated according to the six Spinal 
Instability Neoplastic Score (SINS) criteria (location, pain, 
bone lesion type, spinal alignment, posterolateral element 
involvement, bone lesion type, presence of a baseline 
fracture) to evaluate the predictive significance. 
 
Results: The median spine RT total dose, dose per fraction, 
and number of fractions was 30 Gy (range, 8-60 Gy), 3 Gy 
(range, 1.2-18 Gy), and 10 fraction (range, 1-25), 
respectively. The median follow-up for the entire cohort was 
10 months. Nine percent (23/267) had been previously 
irradiated, 8% (20/267) had a baseline VCF, and 47% (83/176) 
were lytic tumor. In all spinal segments, 33 VCF (33/267, 
12%) were observed following RT, including 21 de novo 
fractures and 11 progressive fractures, and the median time 
to VCF was 4 months. The 1-year fracture free probability 
(FFP) was 85%. Multivariate analysis identified sex (p = 
0.005), metastatic involvement (p = 0.012), prior RT (p = 
0.006), and baseline VCF (p < 0.001) as predictors of VCF. 
Among 176 metastatic spinal segments, we observed 32 
fractures (32/176, 18%) with 1-year FFP of 78.1%. 
Multivariate analysis showed that the risk of VCF in 
metastatic spine segments was statistically significant in 
patients with SINS class II/III with or without pre-existing 
baseline VCF (p < 0.001) and prior RT( p < 0.001). 
 
Conclusion: The risk of VCF is higher in women patients with 
a baseline VCF and prior RT. Additionally, in metastatic spine 
segments, the risk of VCF is significant in patients with SINS 
class II/III with or without pre-existing baseline VCF and prior 
RT. SINS criteria can be used as an option for predicting VCF 
risk before performing RT specific to spinal metastases from 
CRC. 
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Purpose or Objective: Metastatic spinal cord compression 
(MSCC) is a common oncological emergency resulting in 
significant morbidity and detrimental functional outcome. 
Population studies suggest an incidence of 3-7% in men with 
metastatic castrate resistant prostate cancer. In our centre, 
therapy monitoring of established bone disease in breast and 
prostate cancer is undertaken with whole body MRI scanning 
(WB-MRI). WB-MRI includes a dedicated spinal examination 
and diffusion weighted sequences that can aid in earlier 
detection of disease progression or response to treatment. 
The aim of this cross-sectional hypothesis generating study 
was to identify if routine WB-MRI reduces the rates of 
symptomatic MSCC in metastatic breast and prostate cancer 
patients. 
 
Material and Methods: Patients with metastatic breast and 
prostate cancer who underwent ≥2 WB -MRI scans between 
2010-2014 were identified and cross-referenced with patients 
receiving emergency radiotherapy for symptomatic MSCC. 
The number of breast & prostate cancer patients, who had ≥2 
WB-MRI scans and received emergency radiotherapy for MSCC 
were recorded.  
 
Results: 63 patients with breast cancer and 89 patients with 
prostate cancer received emergency radiotherapy for MSCC 
between 2010-2014. Of the 365 patients with breast cancer 
who had ≥2 WB -MRI scans, only 1 (0.3%) patient underwent 
emergency radiotherapy for MSCC. 102 patients with 
metastatic prostate cancer had ≥2 WB -MRI scans of which 2 
(2.0%) had emergency radiotherapy for MSCC. 
 
Conclusion: Rates of symptomatic MSCC in this series of 
patients undergoing regular WB-MRI scans for therapy 
monitoring of bone disease are low.  
Routine WB-MRI may aid in the early detection of disease 
progression in the bones, allowing earlier change in systemic 
therapy or the use of prophylactic radiotherapy particularly 
for incipient cord compression. This data generates the 
hypothesis that WB-MRI may prevent progression of bone 
disease and development of symptomatic MSCC. This has the 
caveats that the population studied was selected and in 
particular had relatively stable disease that permitted the 
routine use of WB-MRI. It is possible that the morphological 
spinal MRI examination component, rather than the diffusion 
weighted sequences, may provide much of the utility of the 
WB-MRI examination. Further prospective studies are 
required to confirm our findings. 
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Purpose or Objective: To assess the effectiveness of a SHort-
course Accelerated RadiatiON therapy (SHARON) in the 
palliative treatment of patients with advanced primary or 
metastatic H&N tumors.  
 
Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group performance status of ≤3. Twenty -three patients were 
treated with H&N radiotherapy at 20 Gy (5 Gy per fraction) in 
2 days with a twice daily fractionation. The primary endpoint 
was the assessment of efficacy in terms of symptoms relief. 
 
Results: Characteristics of the enrolled patients were: 
male/female: 9/14; median age: 83 years (range: 40-98). 
Eastern Cooperative Oncology Group performance status was 
<3 in 11 patients (47.8%). Grade 1-2 acute skin (60.9%) and 
mucositis (39.1%) toxicities were recorded. Only one patient 
(4.3%) experienced grade 3 acute mucositis. With a median 
follow-up time of 4 months (range, 1-32 months) 3 skin grade 
1 and 2 skin grade 2 late toxicities have been observed. Of 
the 23 symptomatic patients, 21 showed an improvement or 
resolution of baseline symptoms (overall palliative response 
rate: 91.3%). Three-month overall survival was 89.7% (median 
survival time: N.R.). Median survival without symptoms 
